Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Bipolar Disorder

    Los Angeles, CA

    Search
    Bipolar Disorder
    Los Angeles, CA
    Show Map
    Map View
    Los Angeles, CA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      28 Bipolar Disorder Trials near Los Angeles, CA

      Power is an online platform that helps thousands of Bipolar Disorder patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Endoxifen for Bipolar Disorder

      Los Angeles,, California
      Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Seizure Disorder, Personality Disorder, Cardiac Conditions, Others
      Must Not Be Taking:Antidepressants, Benzodiazepines, Estrogens, Others

      490 Participants Needed

      Ketogenic Diet for Bipolar Disorder

      Los Angeles, California
      The present study is an open trial of ketogenic diets for adolescents and young adults (ages 12-21 yrs) in the depressive or mixed phases of bipolar disorder (BD). The investigators aim to determine whether combining standard of care pharmacological treatment for bipolar spectrum disorders with a 16-week ketogenic diet is well-tolerated and associated with improvements in depression, inflammatory and metabolic indicators, and executive functioning over the study period. The experimental treatment in this study is a 16-week full ketogenic diet. Four study sites (UCLA, U Cincinnati, U Colorado and U Pittsburgh) will recruit 80 total youth (20 each) from bipolar specialty clinics. All youth eligible for the ketogenic therapy will be provided with the ketogenic diet and standard of care pharmacological treatment. During the diet therapy youth will be seen by a study child/adolescent psychiatrist at least once a month (and more frequently when needed), with the psychiatrist recommending and providing side effects monitoring and pharmacotherapy as clinically indicated. The youth and caregivers will also meet with an expert dietitian who will coach all youth on maintaining the ketogenic diet (low carbs, high fats, medium protein) and making sure the child is tolerating the diet and getting enough liquid and nutrients, following the practice guidelines of the International Ketogenic Diet Study Group for treating youth. All youth and involved caregivers will also be provided will at least one motivational enhancement session to support them in goal setting and completion of the study elements. Throughout the study the investigators will assess metabolic (e.g., blood ketones, HOMA-IR) and inflammatory indicators (e.g., C-reactive protein), both for safety reasons and to assess correlates of symptomatic change. Independent evaluators will assess youth every month regarding their symptoms (depression, mania, anxiety, psychosis), psychosocial functioning, and quality of life. The investigators anticipate that the pilot will transpire over 24 months and be an important step toward establishing feasibility and acceptability of ketogenic therapy for this population, not only in terms of diet administration and compliance but also for obtaining symptomatic, metabolic and inflammatory measurements.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 21

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Diabetes, Eating Disorders, Others
      Must Not Be Taking:SGLT-2 Inhibitors, Insulin, Antihypertensives, Others

      80 Participants Needed

      Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder

      Los Angeles, California
      In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      450 Participants Needed

      VNS for Bipolar Depression

      Los Angeles, California
      This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Psychotic Disorders, Schizophrenia, Bipolar, Dementia, Others

      6800 Participants Needed

      Azetukalner for Bipolar Depression

      Culver City, California
      X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Major Depressive Disorder, Substance Use, Others
      Must Not Be Taking:Antidepressants, Mood Stabilizers

      400 Participants Needed

      KarXT for Bipolar Disorder

      Culver City, California
      This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features. The primary objective of the study is to evaluate the efficacy of KarXT compared to placebo in treating symptoms of mania during a 3-week inpatient period. The duration of the study including screening, the double-blind inpatient treatment period and safety-follow-up is no more than seven weeks.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:BP-II, Major Depression, Substance Use, Others
      Must Not Be Taking:Psychotropics

      274 Participants Needed

      KarXT for Bipolar Disorder

      Culver City, California
      This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Suicidal Behavior, Rapid Cycling, Substance Use, Others

      450 Participants Needed

      BHV-7000 for Bipolar Disorder

      Culver City, California
      The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Medical Condition, Adherence Issues, Risk To Self/others

      200 Participants Needed

      KarXT for Bipolar Disorder

      Culver City, California
      The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Suicidal Risk, Others
      Must Be Taking:Lithium, Valproate, Lamotrigine

      424 Participants Needed

      BHV-7000 for Bipolar Disorder

      Culver City, California
      The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      256 Participants Needed

      Collaborative Decision Skills Training for Serious Mental Illness

      West Los Angeles, California
      Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives. Although traditional treatments tend to focus on symptom remission, Veterans prioritize a range of treatment goals, including personal empowerment and gaining personally meaningful skills. Increasing Veteran-clinician collaboration can help effectively align care with each Veteran's goals and support an empowering therapeutic experience. This project will evaluate the effectiveness of a group-based intervention intended to increase Veterans' comfort, confidence, knowledge, and skills to collaborate with their treatment teams. Findings from this study will contribute important knowledge about this intervention's effectiveness and how to enhance its effectiveness, especially for Veterans from minoritized groups. If the decision-making intervention is effective, it would help Veterans with serious mental illness, and might also help Veterans with other chronic health conditions, like PTSD and chronic pain.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Substance Use, Neurological Disorder, Violence, Others

      119 Participants Needed

      Lumateperone for Bipolar Mania

      Culver City, California
      This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Dementia, Substance Use, Others

      350 Participants Needed

      KarXT for Mania

      Bellflower, California
      The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Suicidal Risk, Others
      Must Not Be Taking:Psychotropics

      274 Participants Needed

      Lumateperone for Pediatric Bipolar Depression

      West Covina, California
      This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Suicidal Risk, Others

      384 Participants Needed

      OLZ/SAM vs. Olanzapine for Schizophrenia or Bipolar Disorder

      Long Beach, California
      To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Major Depressive Episode, Seizure Disorder, Diabetes, Others
      Must Be Taking:Antipsychotics

      220 Participants Needed

      OLZ/SAM for Schizophrenia

      Encino, California
      This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Suicide Risk, Pregnancy, Others
      Must Be Taking:OLZ/SAM

      236 Participants Needed

      Cariprazine for Bipolar Disorder in Youth

      Long Beach, California
      This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Substance Disorder, Seizures, Others
      Must Not Be Taking:Psychotropics, CYP3A4 Inhibitors

      380 Participants Needed

      Cariprazine for Pediatric Schizophrenia

      Long Beach, California
      This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Major Depressive, Schizoaffective, Intellectual Disability, Others

      310 Participants Needed

      Lumateperone for Schizophrenia and Bipolar Disorder

      West Covina, California
      This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Suicidal Risk, Catatonia, Psychotic Features, Others
      Must Be Taking:Psychostimulants

      500 Participants Needed

      Lumateperone for Bipolar Mania

      Torrance, California
      This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Dementia, Substance Use, Others

      350 Participants Needed

      Why Other Patients Applied

      "Over 20 years, I've tried 6+ antidepressants and anti-anxiety meds to no avail. Cymbalta is the ONLY one that has ever made a difference (which I can use because I have bipolar 2, not 1) but it had some other side effects. I've been hesitant to try any trials, but also at a deadend of any relief. So, let's give it a shot."

      ZJ
      Bipolar Disorder PatientAge: 42

      "I have suffered from different mental health issues and have not had very good luck with finding what works best for me. My mental illness is seriously hurting my marriage and home life... I've been reading about new research treatments and think that they might work better than traditional treatments. Excited to try."

      QQ
      Bipolar Disorder PatientAge: 43

      "I've been experiencing bipolar depression since I was a teenager and have tried many treatments that have not helped: SSRIs (Prozac), Wellbutrin, talk therapy. None worked. I've heard great things about ketamine therapy and would really like to try it. I'd like to access it through a clinical trial."

      FM
      Bipolar Disorder PatientAge: 38

      "I am hoping to find some medication to finally help me & my mood disorder. I have tried multiple other options over the years but without much luck of controlling the depression or mania."

      MM
      Bipolar Disorder PatientAge: 40

      "I really would love to be normal. A functioning part of society. It is very hard to hold a job with this condition. I need to be steady. I do NOT like my current meds or ones I've tried before, so new therapies are of interest to me. "

      EC
      Bipolar Disorder PatientAge: 42
      Match to a Bipolar Disorder Trial

      NMRA-335140 for Bipolar Depression

      Torrance, California
      This trial is testing a new medication called NMRA-335140 to see if it can help adults with Bipolar II disorder who are experiencing major depression. The medication aims to improve mood and reduce feelings of depression.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Bipolar I, Schizophrenia, Substance Use, Others
      Must Not Be Taking:Antidepressants, Mood Stabilizers

      60 Participants Needed

      ABBV-932 for Bipolar Disorder

      Anaheim, California
      Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants with bipolar I or II disorder who are currently experiencing a depressive episode will enter the study and be treated with open-label ABBV-932. Approximately 200 adult participants with bipolar I or II disorder will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 for a 26-week treatment period. The treatment period will be followed by a safety follow-up (SFU) period of 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regularly scheduled visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Psychotic Disorders, Substance Use, Others

      200 Participants Needed

      RAP-219 for Bipolar Disorder

      Los Alamitos, California
      This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Schizoaffective, Substance Use, Others

      224 Participants Needed

      BXCL501 for Pediatric Schizophrenia and Bipolar Agitation

      Anaheim, California
      This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Acute Intoxication, Suicide Risk, Others
      Must Not Be Taking:Benzodiazepines, Hypnotics, Antipsychotics

      140 Participants Needed

      ABBV-932 for Bipolar Disorder

      Anaheim, California
      Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide. Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

      Trial Details

      Trial Status:Recruiting
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      160 Participants Needed

      ABBV-932 for Generalized Anxiety Disorder

      Los Alamitos, California
      This trial tests a new medication called ABBV-932 to see how it works in the body and if it is safe for healthy adults and those with anxiety or bipolar disorder.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      72 Participants Needed

      Valbenazine for Tardive Dyskinesia

      Fountain Valley, California
      This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Parkinsonism, Substance Use Disorder, Others
      Must Be Taking:VMAT2 Inhibitors

      50 Participants Needed

      BXCL501 for Schizophrenia and Bipolar Disorder

      Orange, California
      This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with Bipolar Disorders, Schizophrenia, Schizoaffective, and Schizophreniform disorders and correlate them with clinician-assessed ratings.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Serious Medical Illnesses, Substance Use, Personality Disorders, Suicidality, Others
      Must Be Taking:Psychotropic Treatment

      30 Participants Needed

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Bipolar Disorder clinical trials in Los Angeles, CA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Bipolar Disorder clinical trials in Los Angeles, CA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Bipolar Disorder trials in Los Angeles, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Los Angeles, CA for Bipolar Disorder is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Los Angeles, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Bipolar Disorder medical study in Los Angeles, CA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Bipolar Disorder clinical trials in Los Angeles, CA?

      Most recently, we added Collaborative Decision Skills Training for Serious Mental Illness, KarXT for Bipolar Disorder and ABBV-932 for Bipolar Disorder to the Power online platform.

      Is there hope for people with bipolar?

      Absolutely—bipolar disorder is very treatable: with mood-stabilizing medicines plus evidence-based talk therapy and a regular sleep–wake routine, more than 70 % of people achieve long symptom-free stretches and many return to work, school, and satisfying relationships. Sticking with treatment, watching for early warning signs, and using supports such as the Depression & Bipolar Support Alliance greatly increase those odds, so a full, meaningful life is a realistic goal rather than wishful thinking.

      What is the first red flag of bipolar disorder?

      There isn’t one universal “first” symptom, but the earliest red flag doctors see most often is a sudden decrease in the need for sleep—sleeping only a few hours yet feeling unusually energized and unable to shut your mind off. If this change lasts several days, especially when paired with racing thoughts, extra talkativeness, big ideas, or risky spending, it’s time to get a mental-health check-up because catching bipolar disorder early greatly improves treatment success.

      What is the strongest medication for bipolar?

      There isn’t a single “strongest” pill for bipolar disorder; doctors match the medicine to the phase and the person. For acute mania, lithium or valproate often combined with an atypical antipsychotic (e.g., quetiapine, olanzapine) typically works fastest; for bipolar depression, lamotrigine or quetiapine lead, and for long-term prevention lithium remains the gold standard when tolerated. The best regimen is the one that controls your symptoms with acceptable side effects, so choice and dose are always individualized by a psychiatrist who can monitor blood levels and overall health.

      Why do people with bipolar go off their meds?

      People stop bipolar medication for three main clusters of reasons: 1) medication factors—unpleasant side-effects (weight gain, tremor, mental “fog”) or complex dosing that make daily use feel worse than the illness; 2) illness factors—mood swings that create denial (“I’m fine now”) or the euphoric energy of mania that makes pills seem unnecessary or even unwanted; and 3) practical/social factors—cost, stigma, substance use, or a poor fit with the prescribing clinician. Recognizing which cluster is at play helps patients, families, and doctors tailor solutions—whether that’s adjusting the drug, adding psycho-education or reminders, or improving access—rather than assuming the person is simply being “non-compliant.”

      What is unhealthy coping for bipolar people?

      With bipolar disorder, “unhealthy coping” is anything you do to feel better in the moment that ends up disrupting one of three stabilisers: (1) your medication plan, (2) a regular sleep-and-daily routine, or (3) clear, substance-free judgement. Habits that break those stabilisers—skipping meds, drinking or using drugs, staying up late gaming or doom-scrolling, isolating yourself, or chasing risky thrills like overspending—tend to push mood swings harder and make recovery slower; replacing them with steady sleep, sober living, social support, and professional treatment keeps the illness on a shorter, safer leash.

      Can untreated bipolar disorder lead to psychosis?

      Yes. When bipolar mood swings are allowed to build unchecked, they can become so intense that a person loses touch with reality—research shows psychosis occurs in roughly 6 in 10 people with bipolar I and 2 in 10 with bipolar II, usually during extreme mania or depression. Staying on mood-stabilizing medication, keeping a regular sleep schedule, and seeking immediate care if hallucinations or fixed false beliefs emerge greatly reduce this risk and shorten episodes.

      How does a person with bipolar think?

      Thinking in bipolar disorder depends on the phase: during mania the mind races with big, fast ideas and bold confidence, while during depression thoughts slow down, dwell on negatives, and decision-making feels heavy; between episodes most people return to their usual, clear thinking, though some lingering trouble with focus or memory can remain. Recognising these predictable swings—and getting help early with medication, therapy, sleep, and support—makes it easier to manage symptoms and respond to a loved one with understanding instead of frustration.

      Which hormone causes bipolar disorder?

      No single hormone causes bipolar disorder; it is a brain-based mood condition shaped by genetics, life stress, and how different body systems interact. Shifts in thyroid hormone, the stress hormone cortisol, or female sex hormones can nudge symptoms better or worse—which is why doctors often check thyroid levels and watch times like postpartum or menopause—but fixing those levels alone doesn’t cure the disorder.

      What is end stage bipolar disorder?

      “End-stage” (or late-stage) bipolar disorder is an informal term doctors sometimes use for people whose illness has become chronic, treatment-resistant, and functionally disabling: mood swings remain frequent or severe despite multiple therapies, and there may be memory problems, physical health issues, and difficulty living independently. While this stage signals a need for more intensive care—such as combination medications, electro-convulsive or other neuromodulation therapies, cognitive/functional rehabilitation, and strong social supports—it is not a hopeless diagnosis; working closely with a mental-health team can still reduce symptoms and improve quality of life.

      What current research is being done for bipolar disorders?

      Today’s bipolar-disorder research falls into five main streams: scientists are mapping hundreds of risk and “treatment-response” genes, testing rapid-acting medicines such as ketamine and psilocybin, refining brain-stimulation tools like transcranial magnetic stimulation, using smartphone and wearable data to predict mood swings and stabilize sleep-wake cycles, and running early-intervention trials in high-risk teens and young adults. Together, these projects aim not just to explain why bipolar illness occurs but to deliver faster, more personalized treatments and even prevent new episodes before they start.

      Popular Searches

      By Condition

      Depression Clinical Trials in California

      Anxiety Clinical Trials in California

      Schizophrenia Clinical Trials in California

      ADHD Clinical Trials in California

      Bipolar Disorder Clinical Trials in California

      Multiple Sclerosis Clinical Trials in California

      Autism Clinical Trials in California

      Treatment Resistant Depression Clinical Trials in California

      Borderline Personality Disorder Clinical Trials in California

      Social Anxiety Disorder Clinical Trials in California

      Parkinson's Disease Clinical Trials in California

      Alzheimer's Disease Clinical Trials in California

      By Location

      Clinical Trials near Los Angeles, CA

      Clinical Trials near San Francisco, CA

      Clinical Trials near San Diego, CA

      Clinical Trials near Sacramento, CA

      Clinical Trials near La Jolla, CA

      Clinical Trials near Orange, CA

      Clinical Trials near Stanford, CA

      Clinical Trials near Palo Alto, CA

      Clinical Trials near Long Beach, CA

      Clinical Trials near Duarte, CA

      Clinical Trials near Oakland, CA

      Clinical Trials near Torrance, CA

      Other People Viewed

      By Subject

      21 Bipolar Disorder Trials near Cleveland, OH

      32 Bipolar Disorder Trials near Fort Lauderdale, FL

      24 Bipolar Disorder Trials near New York, NY

      21 Bipolar Disorder Trials near Houston, TX

      25 Bipolar Disorder Trials near Dallas, TX

      15 Bipolar Disorder Trials near Philadelphia, PA

      47 Schizophrenia Trials near Los Angeles, CA

      23 Post-Traumatic Stress Disorder Trials near Los Angeles, CA

      Top Clinical Trials near Los Angeles, CA

      Top Clinical Trials near Los Angeles, CA

      Top Prostate Cancer Clinical Trials near Los Angeles, CA

      Top Clinical Trials near Culver City, CA

      By Trial

      Lumateperone for Bipolar Mania

      Multiple Medications for Bipolar Depression

      Ketamine for Treatment-Resistant Bipolar Depression

      Quetiapine for Post-Concussion Syndrome

      Lithium for Parkinson's Disease

      Mindfulness-Based Neurofeedback for Borderline Personality Disorder

      Neratinib + Valproate for Advanced Solid Cancers

      Solriamfetol for Binge Eating Disorder

      Cognitive Rehabilitation for Hoarding Disorder

      Red Blood Cell Exchange for Sickle Cell Disease

      BNT323/DB-1303 for Endometrial Cancer

      New Electrode for Prosthetic Limb Control in Amputees

      Related Searches

      Top Bipolar-disorder Clinical Trials near New York, NY

      Top Bipolar-disorder Clinical Trials near Philadelphia, PA

      Top Bipolar-disorder Clinical Trials near San Diego, CA

      Top Bipolar-disorder Clinical Trials near Washington, DC

      Top Hypertension Clinical Trials near Houston, TX

      Top Hypertension Clinical Trials near Miami, FL

      Self-Management Program for Inflammatory Bowel Disease

      Auricular Vagus Nerve Stimulation for Premature Ventricular Contractions

      Smartphone App for Serious Mental Illness

      BXCL501 for Schizophrenia and Bipolar Disorder

      Central Venous Catheter Techniques for Shock

      Post-PCI FFR for Coronary Artery Disease